How digital is reversing fortunes in R&D -

A new report lays out the ways digital transformation could reverse the trend of declining ROI in pharma R&D. In 2010 the mean cost of bringing a new asset to market was $1.1 billion; in 2018 it was $2.1 billion, with clinical trials making up an increasingly large share of this cost. Meanwhile, the mean projected return on new R&D investments fell to 1.9% from 10.1% in 2010, according to an ongoing analysis by Deloitte. Tom O'Leary, chief information officer at ICON, says there are a number of factors behind this decline in return on investment (ROI). "Costs are continuing to increase as more capabilities become available," he says.